Torrent Pharmaceuticals Ltd Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Torrent Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Torrent Pharmaceuticals Ltd management said on order book — free account, 30 seconds.
Capex plans
Track Torrent Pharmaceuticals Ltd — get its next earnings analysis in your feed
Margin guidance
Order book
How does Torrent Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Torrent Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Torrent Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Torrent Pharmaceuticals Ltd's management said in earlier quarters
- Q4 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…